within Pharmacolibrary.Drugs.ATC.L;

model L04AC07
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.004833333333333333,
    adminDuration  = 600,
    adminMass      = 0.8,
    adminCount     = 1,
    Vd             = 0.0064,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Tocilizumab is a recombinant humanized monoclonal antibody that acts as an interleukin-6 receptor antagonist. It is approved for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, giant cell arteritis, and cytokine release syndrome, and it has been used during the COVID-19 pandemic for severe inflammatory responses. Tocilizumab is administered primarily via intravenous infusion or subcutaneous injection.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters based on two-compartment model in patients with rheumatoid arthritis after a single intravenous dose. The data are pooled from clinical studies in adult human subjects.</p><h4>References</h4><ol><li>Martin Sheppard, Faidra Laskou, Philip P Stapleton, Shahryar Hadavi, Bhaskar Dasgupta,Tocilizumab (Actemra).,Human vaccines & immunotherapeutics,2017<a href='https://pubmed.ncbi.nlm.nih.gov/28841363/'>https://pubmed.ncbi.nlm.nih.gov/28841363/</a></li><li>Monika Tomaszewska-Kiecana, Martin Ullmann, Corinne Petit-Frere, JoÃ«lle Monnet, Christos Dagres, Andras Illes,Pharmacokinetics of a proposed tocilizumab biosimilar (MSB11456) versus US-licensed tocilizumab: results of a randomized, double-blind, single-intravenous dose study in healthy adults.,Expert review of clinical immunology,2023<a href='https://pubmed.ncbi.nlm.nih.gov/36715299/'>https://pubmed.ncbi.nlm.nih.gov/36715299/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L04AC07;
